References

gnck

Колопроктология

Koloproktologia

2073-75562686-7303

Russian Association of Coloproctology

10.33878/2073-7556-2024-23-4-139-147

gnck-1967

Research Article

ОБЗОР ЛИТЕРАТУРЫ

REVIEW

Патогенетические механизмы развития пенетрирующей формы болезни Крона (обзор литературы)

Pathogenetic mechanisms of penetrating Crohn’s disease (review)

https://orcid.org/0000-0003-1180-0524

Белоус

С. С.

Belous

S. S.

к.м.н., гастроэнтеролог, старший научный сотрудник отдела по изучению воспалительных и функциональных заболеваний кишечника

ул. Саляма Адиля, д. 2, г. Москва, 123423, тел.: +7 (499) 199-66-19

Sofia S. Belous

Salyama Adilya st., 2, Moscow, 123423

belous_ss@gnck.ru

https://orcid.org/0000-0003-1697-4670

Выкова

Б. А.

Vykova

B. A.

к.м.н., гастроэнтеролог, заведующая гастроэнтерологическим отделением

ул. Саляма Адиля, д. 2, г. Москва, 123423

Bella A. Vykova

Salyama Adilya st., 2, Moscow, 123423

https://orcid.org/0000-0002-9015-2600

Аносов

И. С.

Anosov

I. S.

к.м.н., заведующий отделом малоинвазивной проктологии

ул. Саляма Адиля, д. 2, г. Москва, 123423

Ivan S. Anosov

Salyama Adilya st., 2, Moscow, 123423

https://orcid.org/0000-0002-8803-7566

Александров

Т. Л.

Aleksandrov

T. L.

к.м.н., гастроэнтеролог, научный сотрудник отдела по изучению воспалительных и функциональных заболеваний кишечника

ул. Саляма Адиля, д. 2, г. Москва, 123423

Timofei L. Aleksandrov

Salyama Adilya st., 2, Moscow, 123423

https://orcid.org/0009-0009-6907-6912

Чупина

П. И.

Chupina

P. I.

хирург-колопроктолог, аспирант 2 года обучения, отделение хирургии воспалительных заболеваний кишечника

ул. Саляма Адиля, д. 2, г. Москва, 123423

Polina I. Chupina

Salyama Adilya st., 2, Moscow, 123423

https://orcid.org/0000-0001-7113-7942

Коргунова

М. В.

Korgunova

M. V.

ординатор 2 года обучения, отдел по изучению воспалительных и функциональных заболеваний кишечника

ул. Саляма Адиля, д. 2, г. Москва, 123423

Maria V. Korgunova

Salyama Adilya st., 2, Moscow, 123423

ФГБУ «НМИЦ колопроктологии им. А.Н. Рыжих» Минздрава РоссиииРоссияRyzhikh National Medical Research Center of ColoproctologyRussian Federation

ФГБУ «НМИЦ колопроктологии им. А.Н. Рыжих» Минздрава РоссииРоссияRyzhikh National Medical Research Center of ColoproctologyRussian Federation

2024

21122024

234139147

2024

Белоус С.С., Выкова Б.А., Аносов И.С., Александров Т.Л., Чупина П.И., Коргунова М.В.

Belous S.S., Vykova B.A., Anosov I.S., Aleksandrov T.L., Chupina P.I., Korgunova M.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.ruproctology.com/jour/article/view/1967

В обзоре литературы освещены патогенетические механизмы развития одного из наиболее тяжелых осложнений, возникающих на фоне хронического активного воспалительного процесса, обусловленного наличием болезни Крона — формирования межкишечных свищей. Дано представление о возможном вкладе в их развитие микробиологического и генетического фактора. Также дана оценка возможного влияния матриксных металлопротеиназ и их тканевых ингибиторов. Одним из наиболее перспективных направлений в настоящее время считается механизм эпителиально-мезенхимального перехода, который способен объяснить формирование свищевой формы болезни Крона. Требуются дальнейшие исследования для выявления наиболее вероятной причины осложненного течения заболевания, что в перспективе позволит разработать подходы к патогенетической терапии у данной группы пациентов.

The review evaluates pathogenesis of intestinal fistulas in Crohn’s disease (CD). An idea of the possible contribution of the microbiological and genetic factor is given. The possible effect of matrix metalloproteinases and their tissue inhibitors also assessed. One of the most promising areas which can explain development of intestinal fistulas in CD is epithelial-mesenchymal transition. Further research is required to identify the cause of the complicated CD, which in future will develop correct approaches to pathogenetic therapy.

БК-ассоциированные свищиэпителиально-мезенхимальный переходпенетрирующая форма

CD-associated fistulasepithelial-mesenchymal transitionpenetrating form

References1

Podolsky DK. Inflammatory bowel disease. N Engl J Med.2002;347:417–29. doi: 10.1056/NEJMra020831

Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101:1274– 82. doi: 10.1111/j.1572-0241.2006.00552.x

Pimentel M, Chang M, Chow EJ, et al. Identification of a prodromal period in Crohn’s disease but not ulcerative colitis. Am J Gastroenterol. 2000;95:3458–62. doi: 10.1111/j.1572-0241.2000.03361.x

Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. JAMA. 1932;1932:1323– 29. doi: 10.1001/jama.1932.02740680019005

Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53. doi: 10.1136/gut.2005.082909

Zhulina Y, Udumyan R, Henriksson I, et al. Temporal trends in nonstricturing and non-penetrating behaviour at diagnosis of Crohn’s disease in Orebro, Sweden: a population-based retrospective study. J Crohns Colitis. 2014;8:1653–60. doi: 10.1016/j.crohns.2014.07.006

Lapidus A. Crohn’s disease in Stockholm County during 1990- 2001: an epidemiological update. World J Gastroenterol. 2006;12:75– 81. doi: 10.3748/wjg.v12.i1.75

Everhov AH, Halfvarson J, Myrelid P, et al. Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden. Gastroenterology. 2018;154:518–28.e15. doi: 10.1053/j.gastro.2017.10.034

Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–83. doi: 10.1038/ajg.2008.168

Torres J, Mehandru S, Colombe lJF, et al. Crohn’s disease. Lancet. 2017;389:1741–55. doi: 10.1016/S0140-6736(16)31711-1

Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95. doi: 10.1056/NEJMoa0904492

Larsen L, Drewes AM, Broberg MCH, et al. Changing infliximab prescription patterns in inflammatory bowel disease: a populationbased cohort study, 1999–2014. Inflamm Bowel Dis. 2018;24:433–39. doi: 10.1093/ibd/izx038

Olivera P, Spinelli A, Gower-Rousseau C, et al. Surgical rates in the era of biological therapy: up, down or unchanged? Curr Opin Gastroenterol. 2017;33:246–53. doi: 10.1097/MOG.0000000000000361

Eberhardson M, Soderling JK, Neovius M, et al. Anti-TNF treat-

ment in Crohn’s disease and risk of bowel resection-a population based cohort study. Aliment Pharmacol Ther. 2017;46:589– 98. doi: 10.1111/apt.14224

Eberhardson M, Myrelid P, Söderling JK, et al. Tumour necrosis factor inhibitors in Crohn’s disease and the effect on surgery rates. Colorectal Dis. 2021. doi: 10.1111/codi.16021 [Epub ahead of print].

Jeuring SF, van den Heuvel TR, Liu LY, et al. Improvements in the long-term outcome of Crohn’s disease over the past two decades and the relation to changes in medical management: results from the population-based IBDSL cohort. Am J Gastroenterol. 2017;112:325–36. doi: 10.1038/ajg.2016.524

van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalization and surgery towards anti-TNF alpha therapy: results from the COIN study. Gut. 2014;63:72–9. doi: 10.1136/gutjnl-2012-303376

Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a populationbased cohort. Gastroenterology. 2010;139:1147– 1155. 19. Schwartz DA, Loftus EVJr., Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875–880.

Maeda K, Okada M, Yao T, et al. Intestinal and extraintestinal complications of Crohn’s disease: predictors and cumulative probability of complications. J Gastroenterol. 1994;29:577–582.

Hellers G, Bergstrand O, Ewerth S, et al. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut. 1980;21:525–7. doi: 10.1136/gut.21.6.525

Schwartz DA, Loftus EVJr., Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875–80. doi: 10.1053/gast.2002.32362

Michelassi F, Stella M, Balestracci T, et al. Incidence, diagnosis, and treatment of enteric and colorectal fistulae in patients with Crohn’s disease. Ann Surg. 1993;218:660– 6. doi: 10.1097/00000658-199321850-00012

Van Backer JT, Lee EC. Enterohepatic fistula in a Crohn’s disease patient: a case report. Int J Surg Case Rep. 2017;39:69–71.

Saborit R, Roig A, Garcia Del Cano J, et al. Ovarian involvement in Crohn’s disease: a rare complication. Rev Esp Enferm Dig. 2016;108:100–103.

West D, Russell TR, Brotman M. Rectalepidural fistula complicating Crohn’s enterocolitis. Dis Colon Rectum. 1983;26:622–624.

Scharl M, Rogler G. Pathophysiology of fistula formation in Crohn’s disease. World J Gastrointest Pathophysiol. 2014;5:205–212.

Schuppan D, Freitag T. Fistulising Crohn’s disease: MMPs gone awry. Gut. 2004;53:622–624.

Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033–2045.

Engelhardt KR, Shah N, Faizura-Yeop I, et al. Clinical outcome in IL-10– and IL-10 receptor–deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2013;131:825–830.

Bataille F, Klebl F, Rümmele P, et al. Morphological characterization of Crohn’s disease fistulae. Gut. 2004;53:1314–1321.

Siegmund B, Feakins RM, Barmias G, et al. Results of the Fifth Scientific Workshop of the ECCO (II): pathophysiology of perianal fistulizing disease. J Crohns Colitis. 2016;10:377–386.

Maggi L, Capone M, Giudici F, et al. CD4þCD161þ T lymphocytes infiltrate Crohn’s disease-associated perianal fistulas and are reduced by anti-TNF-a local therapy. Int Arch Allergy Immunol. 2013;161:81–86.

Lee JM, Dedhar S, Kalluri R, et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973–981.

Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420–1428.

Shook D, Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev. 2003;120:1351–1383.

Nieto MA, Huang RYJ, Jackson RA, et al. EMT: 2016. Cell. 2016;166:21–45.

Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69–84.

LeBleu VS, Taduri G, O’Connell J, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013;19:1047–1053.

Flier SN, Tanjore H, Kokkotou EG, et al. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem. 2010;285:20202–20212.

Jiang H, Shen J, Ran Z. Epithelial-mesenchymal transition in Crohn’s disease. Mucosal Immunol. 2018;11:294–303.

Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033–2045.

Bataille F, Rohrmeier C, Bates R, et al. Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn’s disease. Inflamm Bowel Dis. 2008;14:1514–1527.

Scharl M, Frei S, Pesch T, et al. Interleukin-13 and transforming growth factor b synergise in the pathogenesis of human intestinal fistulae. Gut. 2013;62:63–72.

Leeb SN, Vogl D, Gunckel M, et al. Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology. 2003;125:1341–1354.

Brenmoehl J, Miller SN, Hofmann C, et al. Transforming growth factorbeta 1 induces intestinal myofibroblast differentiation and modulates their migration. World J Gastroenterol. 2009;15:1431– 1442.

Meier JK, Scharl M, Miller SN, et al. Specific differences in migratory function of myofibroblasts isolated from Crohn’s disease fistulae and strictures. Inflamm Bowel Dis. 2011;17:202–212.

Ortiz-Masiá D, Gisbert-Ferrándiz L, Bauset C, et al. Succinate activates EMT in intestinal epithelial cells through SUCNR1: a novel protagonist in fistula development. Cells. 2020;9:1104.

Scharl M, Weber A, Fürst A, et al. Potential role for SNAIL family transcription factors in the etiology of Crohn’s disease-associated fistulae. Inflamm Bowel Dis. 2011;17:1907–1916.

Frei SM, Pesch T, Lang S, et al. A role for tumor necrosis factor and bacterial antigens in the pathogenesis of Crohn’s disease-associated fistulae. Inflamm Bowel Dis. 2013;19:2878–2887.

Bates RC, Bellovin DI, Brown C, et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 2005;115:339–347.

Ortiz-Masià D, Salvador P, Macias-Ceja DC, et al. WNT2b activates epithelial mesenchymal transition through FZD4: relevance in penetrating Crohn’s disease. J Crohns Colitis. 2020;14:230–239.

Frei SM, Hemsley C, Pesch T, et al. The role for dickkopf-homolog-1 in the pathogenesis of Crohn’s disease-associated fistulae. PLoS One. 2013;8:e78882.

Sullivan DE, Ferris M, Pociask D, et al. Tumor necrosis factoralpha induces transforming growth factorbeta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol. 2005;32:342–349.

Bates RC, Mercurio AM. Tumor necrosis factor-a stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell. 2003;14:1790–1800.

Ruffolo C, Scarpa M, Faggian D, et al. Cytokine network in chronic perianal Crohn’s disease and indeterminate colitis after colectomy. J Gastrointest Surg. 2007;11:16–21.

Haddow JB, Musbahi O, MacDonald TT, et al. Comparison of cytokine and phosphoprotein profiles in idiopathic and Crohn’s disease-related perianal fistula. World J Gastrointest Pathophysiol. 2019;10:42–53.

Plevris N, Jenkinson PW, Arnott ID, et al. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn’s disease. Eur J Gastroenterol Hepatol. 2020;32:32–37.

von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000;47:63–73.

Santana A, Medina C, Paz-Cabrera MC, et al. Attenuation of dextran sodium sulphate-induced colitis in matrix metalloproteinase-9 deficient mice. World J Gastroenterol. 2006;12:6464–6472.

Castaneda FE, Walia B, Vijay-Kumar M, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial derived MMP. Gastroenterology. 2005;129:1991–2008.

Goffin L, Fagagnini S, Vicari A, et al. Anti-MMP-9 antibody: a promising therapeutic strategy for treatment of inflammatory bowel disease complications with fibrosis. Inflamm Bowel Dis. 2016;22:2041–2057.

de Bruyn M, Ferrante M, Failure of MMP-9 Antagonists in IBD: demonstrating the importance of molecular biology and wellcontrolled early phase studies. J Crohns Colitis. 2018;12:1011–1013.

Nelson AR, Fingleton B, Rothenberg ML. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135–1149.

Kirkegaard T, Hansen A, Bruun E, et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn’s disease. Gut. 2004;53:701–709.

Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317.

de Lange KM, Moutsianas L, Lee JC, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017;49:256–261.

Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–124.

Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn’s disease patients. Clin Gastroenterol Hepatol. 2009;7:972–980.e2.

Latiano A, Palmieri O, Cucchiara S, et al. Polymorphism of the IRGM gene might predispose to fistulizing behavior in Crohn’s disease. Am J Gastroenterol. 2009;104:110–116.

Cleynen I, González JR, Figueroa C, et al. Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype: results from the IBD chip European Project. Gut. 2013;62:1556–1565.

Franke A, McGovern DP, Barrett JC, et al. Genome-wide metaanalysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42:1118–1125.

Barrett JC, Hansoul S, Nicolae DL, et al. Genome wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955–962.

Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn’s disease patients. Clin Gastroenterol Hepatol. 2009;7:972–980.e2.

Schnitzler F, Friedrich M, Wolf C, et al. The NOD2 single nucleotide polymorphism rs72796353 (IVS4þ10 A > C) is a predictor for perianal fistulas in patients with Crohn’s disease in the absence of other NOD2 mutations. PLoS One. 2015;10:e0116044.

Park HJ, Jung ES, Kong KA, et al. Identification of OCTN2 variants and their association with phenotypes of Crohn’s disease in a Korean population. Sci Rep. 2016;6:22887.

Vermeire S, Pierik M, Hlavaty T, et al. Association of organic cation transporter risk haplotype with perianal penetrating Crohn’s disease but not with susceptibility to IBD. Gastroenterology. 2005;129:1845–1853.

Li Y, Wang Z, Wu X, et al. Intestinal mucosa-derived DNA methylation signatures in the penetrating intestinal mucosal lesions of Crohn’s disease. Sci Rep. 2021;11:9771.

Ananthakrishnan AN, Bernstein CN, Iliopoulos D, et al. Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2018;15:39–49.

West RL, Van der Woude CJ, Endtz HP, et al. Perianal fistulas in Crohn’s disease are predominantly colonized by skin flora: implications for antibiotic treatment? Dig Dis Sci. 2005;50:1260–1263.

Haac BE, Palmateer NC, Seaton ME, et al. A distinct gut microbiota exists within Crohn’s disease–related perianal fistulae. J Surg Res. 2019;242:118–128.

Tozer PJ, Rayment N, Hart AL, et al. What role do bacteria play in persisting fistula formation in idiopathic and Crohn’s anal fistula? Colorectal Dis. 2015;17:235–241.

Cane G, Ginouvès A, Marchetti S, et al. HIF-1alpha mediates the induction of IL-8 and VEGF expression on infection with Afa/ Dr diffusely adhering E. coli and promotes EMT-like behaviour. Cell Microbiol. 2010;12:640–653.

Chandrakesan P, Roy B, Jakkula LU, et al. Utility of a bacterial infection model to study epithelial-mesenchymal transition, mesenchymal epithelial transition or tumor genesis. Oncogene. 2014;33:2639–2654.

Jain U, Ver Heul AM, Xiong S, et al. Debaryomyces is enriched in Crohn’s disease intestinal tissue and impairs healing in mice. Science. 2021;371:1154–1159.

Ratto C, Litta F, Lucchetti D, et al. Immunopathological characterization of cryptoglandular anal fistula: a pilot study investigating its pathogenesis. Colorectal Dis. 2016;18:O436–O444.

van Onkelen RS, Gosselink MP, van Meurs M, et al. Proinflammatory cytokines in cryptoglandular anal fistulas. Tech Coloproctol. 2016;20:619–625.

Аносов И.С., Ерышева Т.А., Хрюкин Р.Ю., и соавт. Мезенхимальные стволовые клетки в лечении свищей перианальной области при болезни Крона (систематический обзор литературы и метаанализ). Колопроктология. 2024;23(3). doi: 10.33878/2073-7556-2024-23-3-100-111

Anosov I.S., Eryshova T.A., Khryukin R.Yu., et al. Mesenchymal stem cells for perianal fistulizing Crohn’s disease (systematic review and meta-analysis). Koloproctologia. 2024; 23(3). (in Russ.). doi: 10.33878/2073-7556-2024-23-3-100-111

The authors declare that there are no conflicts of interest present.